4-[2-(4-Cyanophenyl)-3-[1-(1,4-diazepan-1-yl)ethyl]imidazo[1,2-a]pyridin-6-yl]benzonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-[2-(4-Cyanophenyl)-3-[1-(1,4-diazepan-1-yl)ethyl]imidazo[1,2-a]pyridin-6-yl]benzonitrile
• 英文别名: 4-[2-(4-cyanophenyl)-3-[1-(1,4-diazepan-1-yl)ethyl]imidazo[1,2-a]pyridin-6-yl]benzonitrile
• 化学式: C₂₈H₂₆N₆
• 分子量: 446.5
• InChiKey: WEEPNEXRKGELIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  80.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY
  申请人：Mulbaier Marcel

  公开号：US20140221354A1

  公开（公告）日：2014-08-07

  The present invention provides novel imidazo[1,2-a]pyridine compounds that are useful in therapy of diseases and disorders. The novel compounds inhibit the activation of Hypoxia Inducible Factor (HIF)-mediated transcription and signaling under hypoxic conditions. In one aspect, the compounds of the present invention are useful for the preparation of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization. Also provided is a pharmaceutical composition, comprising a compound of the invention and a second therapeutic agent or radiation, useful for the treatment or prevention of the mentioned diseases or disorders, wherein X is CH 2 , CH 2 CH 2 or C═O; R 1 is phenyl or C-bound monocyclic 5- or 6-membered heteroaryl, wherein phenyl and monocyclic 5- or 6-membered heteroaryl are unsubstituted or carry 1, 2, 3, 4 or 5 radicals R 1a which are identical or different; R 2 is phenyl or C-bound monocyclic 5- or 6-membered heteroaryl, wherein phenyl and monocyclic 5- or 6-membered heteroaryl are unsubstituted or carry 1, 2, 3, 4 or 5 radicals R 2a which are identical or different; R 3 is hydrogen, C 1 -C 6 -alkyl, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl, fluorinated C 1 -C 2 -alkyl C(O)R 4 ; where R 1a , R 2a and R 4 are as defined in the claims and the specification.

  本发明提供了新型咪唑[1,2-a]吡啶化合物，用于治疗疾病和疾病障碍。这些新型化合物抑制缺氧条件下缺氧诱导因子（HIF）介导的转录和信号的激活。在一个方面，本发明的化合物可用于制备治疗或预防炎症性疾病、高增殖性疾病或疾病障碍、缺氧相关病理和过度血管化疾病的药物。还提供了一种药物组合物，包括本发明的化合物和第二种治疗剂或辐射，用于治疗或预防上述疾病或疾病障碍，其中X为CH2、CH2CH2或C═O；R1为苯基或C-结合的单环5-或6-成员杂环，其中苯基和单环5-或6-成员杂环未被取代或携带1、2、3、4或5个相同或不同的R1a基团；R2为苯基或C-结合的单环5-或6-成员杂环，其中苯基和单环5-或6-成员杂环未被取代或携带1、2、3、4或5个相同或不同的R2a基团；R3为氢、C1-C6-烷基、C1-C4-烷氧基-C1-C4-烷基、氟化C1-C2-烷基C(O)R4；其中R1a、R2a和R4如权利要求和说明书中所定义。